Back to Results

A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid Tumors

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Eligibility

patients must have germline or somatic mutation in DDR genes, actionable mutation in PTEN gene or hotspot mutation in the PIK3CA gene

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Jennifer Diamond,  MD

Jennifer Diamond, MD

Study ID

Protocol Number: 19-1987

More information available at ClinicalTrials.gov: NCT03842228

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers